Engineering Extracellular Vesicles: Scaffolds for Therapeutic Cargo

Added:

Translational Bottlenecks and Immunogenicity of Scaffold-Engineered EVs

While engineering extracellular vesicles (EVs) with membrane scaffolds is a promising approach for targeted delivery, a significant counter-perspective warns against 'over-engineering.' Critics highlight that modifying EV membranes with chimeric scaffold proteins can alter their natural tropism, leading to unpredictable off-target effects. Additionally, introducing foreign or highly modified protein domains increases the risk of immunogenicity, potentially triggering host immune clearance upon repeated dosage. From an industrial and clinical standpoint, scaffold-engineered EVs face major scalability and quality control hurdles. Achieving uniform cargo loading, maintaining membrane integrity, and purifying these complex biological entities is immensely challenging compared to highly standardized synthetic alternatives, such as lipid nanoparticles (LNPs). Consequently, some researchers argue that the therapeutic focus should remain on unmodified native EVs or simpler, non-covalent loading methods to preserve safety, predictability, and manufacturability.

Fundamental biology and biogenesis of extracellular vesicles (EVs), such as exosomes and microvesicles, and their natural roles in intercellular communication.
Principles of molecular biology and genetic engineering, specifically the design of fusion proteins and recombinant DNA technology.
Basic concepts of membrane biology, including protein-lipid interactions and membrane-anchoring domains (e.g., GPI anchors, transmembrane domains).
Core principles of drug delivery systems, including targeting strategies, physiological barriers, and biocompatibility.
Advanced active and passive cargo loading methodologies for non-protein molecules, such as therapeutic nucleic acids (mRNA, siRNA, and CRISPR/Cas9 systems).
Strategies for active targeting of engineered EVs to specific tissues or organs using homing peptides or monoclonal antibodies.
Bioprocessing, scalability, and purification techniques required for the clinical-grade manufacturing of therapeutic extracellular vesicles.
Regulatory frameworks and current clinical trials evaluating engineered EV-based therapies for oncology, immunology, and regenerative medicine.
916 views15likes1:01:52@ExtracellularVesicleClubOriginal Release: 2021-05-12

Codiak BioSciences developed a versatile platform for generating engineered extracellular vesicles with defined therapeutic properties by identifying novel scaffolds (EWI subfamily proteins and MARX family proteins) through proteomic analysis of high-purity EV isolates, enabling efficient surface display and lumenal packaging of diverse therapeutic cargoes including proteins, RNAs, and small molecules for potential clinical applications in cancer immunotherapy and vaccines.